APA
O'Hara M. H., Messersmith W., Kindler H., Zhang W., Pitou C., Szpurka A. M., Wang D., Peng S., Vangerow B., Khan A. A., Koneru M. & Wang-Gillam A. (2020). Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. : Journal of pancreatic cancer.
Chicago
O'Hara Mark H, Messersmith Wells, Kindler Hedy, Zhang Wei, Pitou Celine, Szpurka Anna M, Wang Dan, Peng Sheng-Bin, Vangerow Burkhard, Khan Anis A, Koneru Mythili and Wang-Gillam Andrea. 2020. Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. : Journal of pancreatic cancer.
Harvard
O'Hara M. H., Messersmith W., Kindler H., Zhang W., Pitou C., Szpurka A. M., Wang D., Peng S., Vangerow B., Khan A. A., Koneru M. and Wang-Gillam A. (2020). Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. : Journal of pancreatic cancer.
MLA
O'Hara Mark H, Messersmith Wells, Kindler Hedy, Zhang Wei, Pitou Celine, Szpurka Anna M, Wang Dan, Peng Sheng-Bin, Vangerow Burkhard, Khan Anis A, Koneru Mythili and Wang-Gillam Andrea. Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. : Journal of pancreatic cancer. 2020.